Patrick Mooney, head of Novartis’ US eye care business, lays out Novartis’ plans following the spin-out of Alcon and bid to acquire the former Shire ophthalmology franchise from Takeda. Where does Novartis see future growth in eye care? Will ophthalmologists and optometrists see a difference? Is Novartis done acquiring products for a while?